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Abstract
Purpose—Alterations in the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway are major
drivers in colon and rectal carcinogenesis. In colorectal cancer, BRAF mutation is associated with
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microsatellite instability (MSI), and typically predicts inferior prognosis. We examined the effect
of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer.
Methods—We assessed status of BRAF c.1799T>A (p.V600E) mutation and MSI in 506 stage
III colon cancer patients enrolled in a randomized adjuvant chemotherapy trial [5-fluorouracil and
leucovorin (FU/LV) vs. irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional
hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical
features, adjuvant chemotherapy arm and MSI status.
Results—Compared to 431 BRAF-wild-type patients, 75 BRAF-mutated patients experienced
significantly worse overall survival [OS; log-rank p=0.015; multivariate hazard ratio (HR)=1.66;
95% confidence interval (CI), 1.05-2.63]. By assessing combined status of BRAF and MSI, it
appeared that BRAF-mutated MSS (microsatellite stable) tumor was an unfavorable subtype, while
BRAF-wild-type MSI-high tumor was a favorable subtype, and BRAF-mutated MSI-high tumor
and BRAF-wild-type MSS tumor were intermediate subtypes. Among patients with BRAF-mutated
tumors, a non-significant trend toward improved OS was observed for IFL vs. FU/LV arm
(multivariate HR=0.52; 95% CI, 0.25-1.10). Among patients with BRAF-wild-type cancer, IFL
conferred no suggestion of benefit beyond FU/LV alone (multivariate HR=1.02; 95% CI,
0.72-1.46).
Conclusions—BRAF mutation is associated with inferior survival in stage III colon cancer.
Additional studies are necessary to assess whether there is any predictive role of BRAF mutation
for irinotecan-based therapy.
Keywords
colorectal cancer; RAS; biomarker; prognosis; response; resistance
INTRODUCTION
BRAF is a part of the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway. BRAF
mutations are observed in 10-20% of colon cancers in population-based studies (1-9). In
colon cancer, BRAF mutation is associated with proximal tumor location and microsatellite
instability (MSI) (1, 3, 10-13), and with significantly worse patient survival in most (1, 6,
14-22), though not all studies (2). In contrast, MSI-high colon cancers have been associated
with a significantly improved survival (1, 2, 6, 16, 23), and several studies have suggested
the prognostic impact of BRAF mutation status may vary according to the concurrent
presence or absence of MSI-high (1, 14, 21). Thus, investigation of the prognostic impact of
BRAF mutation or MSI in colon cancer may be most informative when these markers are
simultaneously assessed.
The predictive role of BRAF mutation in colon cancer remains less clear. Few studies have
examined the impact of BRAF mutation on the efficacy of available chemotherapy regimens
(24, 25). A recent analysis of stage III colon cancer patients enrolled in a randomized trial
comparing 5-fluorouracil (5-FU) and leucovorin (FU/LV) to irinotecan (CPT11), 5-FU and
leucovorin (IFL) (CALGB 89803) suggested that, among patients with MSI-high cancer,
IFL conferred a superior disease-free survival when compared to FU/LV (23). In light of the
association between BRAF mutation and MSI, we hypothesized that BRAF mutation in colon
cancer may similarly influence the efficacy of irinotecan-based chemotherapy in this setting.
We therefore examined prognostic and predictive roles of BRAF mutation among stage III
colon cancer patients enrolled in this National Cancer Institute (NCI)-sponsored randomized
clinical trial comparing postoperative adjuvant FU/LV to IFL (CALGB 89803) (26). Since
data on pathologic stage, performance status, post-operative treatment, follow-up and tumor
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molecular features such as KRAS and MSI status were carefully recorded in this trial, the
simultaneous impact of disease characteristics and the use of adjuvant therapy could be
assessed to control for potential confounding. Moreover, the simultaneous impact of BRAF
mutational status and MSI on patient outcome could be explored.
MATERIALS AND METHODS
Study population
Patients in this study were participants in the National Cancer Institute (NCI)-sponsored
Cancer and Leukemia Group B (CALGB) adjuvant therapy trial for stage III colon cancer
comparing therapy with the weekly Roswell Park regimen of 5-FU and leucovorin (FU/LV)
to weekly bolus regimen of irinotecan, 5-FU, and leucovorin (IFL) (CALGB 89803) (26).
Between April 1999 and May 2001, 1,264 patients were enrolled on the treatment trial.
Patients in the treatment trial (and thus this companion study) were eligible if they
underwent a complete surgical resection of the primary tumor within 56 days prior to study
entry, and had regional lymph node metastases (stage III colon cancer) but no evidence of
distant metastases. Moreover, patients were required to have a baseline Eastern Cooperative
Oncology Group (ECOG) performance status of 0-2 (ambulatory) and have adequate bone
marrow, renal and hepatic function. Data on family history of colorectal cancer in first-
degree relatives were obtained by questionnaire at diagnosis (26). The current analysis was
limited to 506 patients for whom archived formalin-fixed paraffin-embedded tumor tissue
and BRAF sequencing data were available. All patients signed informed consent, approved
by each site’s institutional review board.
We compared baseline characteristics of the patients who were included in this study (with
available BRAF data, N=506) with those who were excluded from this study due to
unavailability of tissue data (N=758). We did not detect any significant or substantial
difference between these two groups in terms of age, sex, body mass index (BMI), family
history, tumor location, pT stage, pN stage, performance status, bowel perforation, bowel
obstruction or treatment arm (all p>0.08). In addition, recurrence-free and disease-free
survival did not significantly differ in subjects with available BRAF data as compared to
those without BRAF data (multivariate HR=0.96; 95% CI, 0.79-1.18; and multivariate
HR=0.95; 95% CI, 0.78-1.15, respectively).
As part of the quality assurance program of the CALGB, members of the Audit Committee
visit all participating institutions at least once every three years to review source documents.
The auditors verify compliance with federal regulations and protocol requirements,
including those pertaining to eligibility, treatment, adverse events, tumor response, and
outcome in a sample of protocols at each institution. Such on-site review of medical records
was performed for a subgroup of 328 patients (26%) of the 1264 patients included in this
study.
Definitions of study endpoints
The study endpoints were; (1) recurrence-free survival (RFS), defined as the time from the
study enrollment to tumor recurrence or occurrence of a new primary colon tumor; (2)
disease-free survival (DFS), defined as time from the study enrollment to tumor recurrence,
occurrence of a new primary colon tumor, or death from any cause; and (3) overall survival
(OS), defined as the time from the study enrollment to death from any cause. For RFS,
patients who died without known tumor recurrence were censored at last documented
evaluation by a treating provider.
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DNA extraction from tumor, BRAF and KRAS sequencing, and MSI, MLH1 and MSH2
analyses
Tumor molecular analyses were performed blinded to patient and outcome data. DNA was
extracted from paraffin-embedded colon cancer tissue (27). We marked tumor areas on H&E
slide, and dissected tumor tissue by a sterile needle. PCR and Pyrosequencing spanning
BRAF codon 600 (28), and KRAS codons 12 and 13 were performed as previously described
(27) in the laboratory at the Dana-Farber Cancer Institute. Our previous study (27) has
shown that Pyrosequencing assay is more sensitive than Sanger sequencing (29), and can
detect approximately 5-10% of mutant allele among a mixture of mutant and normal alleles.
Microsatellite instability (MSI) was assessed by PCR for 10 markers, and MLH1 and MSH2
expression was examined by immunohistochemistry as previously described (23). Tumors
with instability in ≥50% of the loci were classified as MSI-high, and those with instability in
0-40% of the loci as microsatellite stable (MSS), and the concordance between MSI testing
and immunohistochemistry for MLH1 or MSH2 loss was 97% (23). For 28 cases without
PCR MSI results, those with loss of MLH1 or MSH2 were classified as MSI-high, and those
with intact expression of MLH1 and MSH2 as MSS. All tumor tissue analyses were
performed completely blinded to data patient identity, clinical and outcome data.
Statistical analyses
The goal of this correlative study was to determine whether tumor BRAF mutation status
was associated with clinical outcome for patients with stage III colon cancer. Patient
registration and clinical data collection were managed by the CALGB Statistical Center, and
analyses were conducted collaboratively between the CALGB Statistical Center and Dana-
Farber Cancer Institute. All analyses were based on the study database frozen on November
9, 2009, except for the tumor BRAF data. All analyses used SAS version 9.2 (SAS Institute,
Cary, NC) and all p values were two-sided.
The Kaplan-Meier method was used to estimate the distribution of survival time according
to BRAF status, and the log-rank test was used to compare survival between subgroups. We
used the multivariable Cox proportional hazards model to estimate survival hazard ratio
(HR) by tumor BRAF status. The following variables were considered in the multivariable
analysis: age at study entry (continuous), sex, baseline body mass index (BMI; ≥30 vs. <30
kg/m2), family history of colorectal cancer in first-degree relatives (present vs. absent),
baseline performance status (0 vs. 1-2), presence of bowel perforation or obstruction at time
of surgery, treatment arm, tumor location (proximal vs. distal), pT stage (pT1-2 vs. pT3 vs.
pT4 vs. unknown), pN stage (pN1 vs. pN2), KRAS (wild-type vs. codon 12 mutation vs.
codon 13 mutation), and MSI status (high vs. MSS). A backward stepwise elimination with
a threshold of p=0.20 was conducted to select covariates in the final model. pT stage was
used as a stratifying variable using the strata option in the SAS “proc phreg” command. No
collinearity was evident among the variables studied. Although KRAS and BRAF mutations
were almost mutually exclusive (Table 1) and KRAS mutation overall did not influence
outcome in this dataset (30), we included KRAS codon 12 and 13 mutations separately in the
model, to examine codon-specific effects of KRAS mutation. The proportionality of hazards
assumption was assessed using standard survival plots and by evaluating a time-dependent
variable, which was the cross-product of BRAF and survival time (p=0.011 for RFS; p=0.22
for DFS; p=0.26 for OS). Data were missing on family history in 1% of patients, tumor
location in 1% of patients, pN stage in 0.6% of patients, perforation status in 1.8% of
patients, obstruction status in 0.6% of patients, and MSI status in 0.2% of patients; those
were included in a majority category in multivariable Cox models to maximize the
efficiency of multivariable analyses. To assess the potential differential effect of treatment
arm according to BRAF status (or combined BRAF and MSI status), we performed a single
multivariate Cox regression analysis, in which we could estimate the effect of treatment arm
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simultaneously in two strata of BRAF status (or in four strata of combined BRAF and MSI
status) using a re-parameterization of the interaction term(s) (3). Interaction was also
assessed by including the cross product of BRAF and another variable of interest (without
data-missing cases) in a multivariate model, using the Wald test.
RESULTS
BRAF mutation in stage III colon cancer
Study participants were drawn from a multi-center study of post-operative adjuvant
chemotherapy in stage III colon cancer patients who underwent a curative-intent surgical
resection (CALGB 89803 protocol) (26). We included 506 cases in the current study based
on availability of tumor tissue for BRAF sequencing, which detected c.1799T>A (p.V600E)
mutation in 75 (15%) patients. This BRAF mutation frequency is comparable to data in the
previous large population-based studies in the U.S. (1, 16). Table 1 summarizes baseline
characteristics according to BRAF mutation status. BRAF mutation was significantly
associated with female sex, older age, proximal tumor location, microsatellite instability
(MSI)-high, and wild-type KRAS (all p<0.0045; a p value for significance was adjusted to
p=0.0045 by Bonferroni correction).
Prognostic role of BRAF mutation
With median follow-up of 7.6 years among survivors, there were 183 events for recurrence-
free survival (RFS) analysis, 202 events for disease-free survival (DFS) analysis, and 160
events for overall survival (OS) analysis. In a Kaplan-Meier analysis (Figure 1), BRAF-
mutated cases experienced a non-significant trend towards inferior RFS and DFS. For
BRAF-mutated vs. wild-type cases, 5-year RFS was 60% vs. 65%, and 5-year DFS was 55%
vs. 64%, respectively. BRAF mutation was associated a statistically significant reduction in
OS (5-year OS: 63% in BRAF-mutant vs. 75% in BRAF-wild-type; log-rank p=0.015).
In multivariate Cox regression analysis, we examined the prognostic association of BRAF
mutation adjusting for other predictors of patient survival (Table 2). Compared to BRAF-
wild-type cases, BRAF-mutated cases experienced a significantly worse OS [multivariate
hazard ratio (HR)=1.66; 95% confidence interval (CI), 1.05-2.63], adjusting for other factors
including MSI and KRAS mutational status. For RFS and DFS analyses, trends were similar
in direction, but not statistically significant.
We also examined the associations of MSI and KRAS mutation with patient outcome.
Although MSI-high tumors were independently associated with an improved OS
[multivariate hazard ratio (HR)=0.61; 95% CI, 0.38-0.97], adjusting for other factors
including BRAF and KRAS mutational status, KRAS mutations in either codon 12 or codon
13 were not associated with patient outcome.
Combined BRAF and MSI status, and prognosis
We further categorized patients according to both BRAF and MSI status to assess the joint
effect on patient outcome (Table 3). Compared to patients whose tumors were both BRAF-
wild-type and MSS (microsatellite stable), those with BRAF-mutated and MSS tumors
experienced a trend towards an inferior OS (multivariate HR=1.61; 95% CI, 0.96-2.69). In
contrast, compared to BRAF-wild-type MSS patients, those with BRAF-wild-type MSI-high
tumors demonstrated consistent trends toward superior RFS, DFS, and OS. Finally, patients
with BRAF-mutated MSI-high cancers experienced no significant difference in outcome
when compared to BRAF-wild-type MSS patients [multivariate hazard ratio (HR)=1.02;
95% CI, 0.54-1.93], suggesting opposing prognostic effects of BRAF mutation and MSI-
high.
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Predictive role of BRAF mutation for irinotecan-based therapy
We assessed the prognostic role of BRAF mutation within each treatment arm and the effect
of treatment according to BRAF status. Among patients treated with FU/LV, the presence of
BRAF mutation was associated with a significantly reduced DFS and OS (multivariate OS
HR=2.43; 95% CI, 1.34-4.40) when compared BRAF wild-type tumors (Table 4). In
contrast, among subjects treated with IFL, BRAF mutation was not significantly associated
with patient outcome (multivariate OS HR=1.24; 95% CI, 0.67-2.31; vs. BRAF-wild-type).
Among patients with BRAF-mutated tumors, we observed a non-significant trend toward
improved RFS, DFS, and OS for subjects treated with IFL when compared with FU/LV
(Table 4); however, statistical power was limited and results should be interpreted with
caution. Among patients with BRAF wild-type cancer, IFL was associated with no benefit
when compared to FU/LV alone.
In a Kaplan-Meier analysis by treatment arm and BRAF status (Figure 1), BRAF-mutated
cases treated with FU/LV experienced a significantly worse OS compared to BRAF-mutated
cases treated with IFL or to BRAF-wild-type cases in either treatment arm (log-rank
p=0.030).
Predictive role of combined BRAF and MSI subtyping for irinotecan-based therapy
We examined the predictive role of combined BRAF and MSI status on adjuvant treatment
efficacy (Table 5). Among subjects with either BRAF-wild-type MSS tumors or BRAF-
mutated MSI-high tumors, IFL was not associated with any improvement in patient
outcome. Although statistical power was limited, among patients with either BRAF-wild-
type MSI-high tumors or BRAF-mutated MSS tumors, IFL appeared to confer a consistent
trend toward improved RFS, DFS, and OS when compared to FU/LV-treated subjects. In
contrast, there appeared to be no appreciable benefit of IFL (compared to FU/LV) among
BRAF-mutated MSI-high or BRAF-wild-type MSS patients.
We also performed analyses for response to IFL (vs. FU/LV) according to MSI status
(Supplementary Table 1, Supplementary Figure 1) in the current dataset. There might be a
possible beneficial effect of IFL in MSI-high patients, similar to the previous analysis in the
CALGB 89803 trial (23).
Finally, we examined treatment effects according to status of BRAF mutation and MLH1
and MSH2 by immunohistochemistry (IHC) with available IHC data. There were 4 cases
with MSH2 loss, and all those 4 cases were BRAF-wild-type and likely Lynch syndrome
cases. There were 37 cases of MLH1 loss. Among those 37 cases, 17 cases were BRAF-
wild-type and included Lynch syndrome cases. Among the 4 cases with MSH2 loss, 2 cases
received IFL with no RFS, DFS or OS event (follow-time, 8.1 and 8.5 years). Among the
other 2 cases with MSH2 loss in the FU/LV arm, one case experienced a RFS/DFS/OS event
at 3.5 years, and the other case was censored at 6.7 years. We analyzed the effects of IFL
(vs. FU/LV) in the 17 cases with MLH1 loss and wild-type BRAF, and multivariate HR
(with 95% CI) for IFL treatment (vs. FU/LV) was 0.11 (0.011-1.08) for RFS; 0.11
(0.011-1.07) for DFS; 0.33 (0.021-5.40) for OS. These data were suggestive of good
response of Lynch syndrome cases to IFL (vs. FU/LV), although statistical power was
limited.
DISCUSSION
In this study of patients with stage III colon cancer participating in the randomized trial
comparing post-operative IFL to FU/LV, somatic mutations in BRAF were associated with a
statistically significant reduction in OS, with a non-significant trend toward an inferior RFS
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and DFS. These results persisted in multivariate analyses that adjusted for other predictors
for patient outcome, supporting BRAF mutation as an independent prognostic marker in
colon cancer. Furthermore, combined BRAF and MSI subtyping analysis suggests that
BRAF-mutated MSS tumor is an unfavorable subtype, while BRAF-wild-type MSI-high
tumor is a favorable subtype, and BRAF-mutated MSI-high and BRAF-wild-type MSS
tumors are intermediate subtypes (Figure 1G). The independent, opposing prognostic effects
of BRAF mutation and MSI observed in the current study is also consistent with several
previous studies (6, 16-20, 22).
Interestingly, the prognostic association of BRAF mutation appeared to be somewhat
attenuated among patients treated with IFL, whereas BRAF mutation was associated with a
significant increase in mortality among subjects treated with FU/LV. Among patients with
BRAF-mutated colon cancer, IFL might be associated with a non-significant trend toward
improved RFS, DFS, and OS compared to FU/LV, whereas there was no apparent benefit by
IFL among BRAF wild-type cases. However, statistical power was quite limited and caution
must be taken to interpret the results. Additional studies are needed to examine the
predictive role of BRAF mutation in colon cancer.
Although a number of studies (31-34) have assessed potential predictive roles of various
genetic or tumor biomarkers for irinotecan therapy [e.g., APTX expression (31), ABCB1
polymorphism (32), EGFR and ERCC1 mRNA expression (33)], none of these markers has
yet been proven to be clinically useful. A previous analysis of patients in this clinical trial
suggested that MSI-high might predict an improved patient outcome for treatment with IFL
relative to FU/LV (23), although this finding was not observed in a concurrent trial
conducted in Europe (35). Possibly, mismatch repair deficiency may cause DNA repair gene
mutations, inhibit the DNA repair process for double strand breaks induced by irinotecan,
and thereby potentiate tumor cell death (23).
Analysis of interactions between host factors (e.g., therapy) and tumor markers is
increasingly important in cancer research (36, 37). A few previous studies have examined
the influence of BRAF status on the effect of chemotherapy in colon cancer (24, 25). In the
largest previous analysis, the QUASAR trial (25) observed no predictive role of BRAF
mutation for 5-FU-based chemotherapy in stage II colorectal cancer. The MRC FOCUS trial
(24) observed greater treatment effects with 5-FU plus oxaliplatin (vs. 5-FU alone) in
advanced colorectal cancers with BRAF mutations, compared to smaller effects of 5-FU plus
oxaliplatin (vs. 5-FU alone) in BRAF-wild-type cases. In contrast, there was a greater
treatment effects on progression-free survival with 5-FU plus irinotecan (vs. 5-FU alone) in
advanced colorcetal cancer with wild-type BRAF, compared to smaller effects on
progression-free survival with 5-FU plus irinotecan (vs. 5-FU alone); however, there was no
significant interaction between BRAF mutation and any of the treatment comparisons (24).
Additional studies are necessary to assess efficacy of various treatment regimens in stage III
or IV colorectal cancers. A number of studies have assessed a predictive role of BRAF status
in targeted therapy against EGFR in stage IV colorectal cancer (38-41); BRAF mutation may
have a predictive role for anti-EGFR therapy in monotherapy or in chemorefractory patients,
but its predictive role for other settings remains to be fully determined.
Evidence suggests increased sensitivity of cells with defective mismatch repair to irinotecan
(42, 43), and improved response of Lynch syndrome MSI-high cancers to 5-FU-based
chemotherapy (44). On the other hand, mechanisms underlying the apparent improved
outcome for patients with BRAF-mutated colon cancers treated with irinotecan remain
speculative. BRAF mutation in colon cancer has been associated with high-level global DNA
methylation (45) as well as widespread gene promoter methylation termed the CpG island
methylator phenotype (CIMP)-high (46-49). A recent laboratory analysis found that
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increasing levels of DNA methylation substantially increased sensitivity of cancer cells to
camptothecin whereas widespread hypomethylation induced resistance to camptothecin (50).
Thus, responsiveness of BRAF-mutated cells to irinotecan may reflect increased DNA
methylation associated with BRAF mutation. Confirmation of our observations and
elucidation of the exact mechanisms underlying potential responsiveness of BRAF-mutated
cells to irinotecan await future studies.
There are several advantages in evaluating prognostic and predictive roles of molecular
biomarkers in this NCI-sponsored clinical trial of adjuvant chemotherapy. All patients had
stage III colon cancer, reducing the impact of heterogeneity by disease stage. Moreover,
treatment and follow-up care were all standardized within the clinical trial, and the date and
nature of recurrence were prospectively recorded. In addition, detailed information on other
prognostic variables was routinely collected at study entry.
We recognize that patients who enroll in randomized trials may differ from the population-
at-large. To participate, patients must meet eligibility criteria, be selected as an appropriate
candidate, and be motivated to participate. In addition, patients were particularly selected for
this study on the basis of availability of colon cancer tissue specimens. Nonetheless,
demographic data of the patients in this study did not suggest considerable selection bias.
Moreover, because the study included patients from both community and academic centers
across North America, our findings should reflect the general population of stage III patients
in North America. In addition, although data on BRAF mutational status were available on a
subset of patients enrolled in the trial, baseline characteristics and patient survival did not
substantially differ for patients with and without available archived tumor tissue in this trial.
Finally, since BRAF status was not available on all patients, statistical power was attenuated.
As such, confirmation of our findings is clearly needed.
In conclusion, we found that BRAF mutation was associated with an inferior prognosis in
stage III colon cancer patients, supporting tumor BRAF mutation as an independent
prognostic biomarker in colon cancer. Although BRAF mutation in stage III colon cancer
may possibly predict improved response to irinotecan-based chemotherapy, the predictive
role of BRAF mutation testing remains uncertain at this time, and additional trial studies are
needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
BRAF mutation is associated with microsatellite instability (MSI) in colon cancer. Thus,
the prognostic role of BRAF mutation or MSI in colon cancer can only be properly
assessed when these markers are simultaneously determined. We examined BRAF
mutation status in stages III colon cancer patients who enrolled in a phase III trial
CALGB 89803, which randomized patients to either a combination of irinotecan, 5-
fluorouracil, and leucovorin (IFL) or 5-fluorouracil, and leucovorin (FU/LV). We found
that BRAF mutation was independently associated with inferior overall survival. We also
observed a non-significant trend toward an improved overall survival of patients
randomized to IFL (vs. FU/LV) among BRAF-mutated patients, but not among BRAF-
wild-type patients. Our findings provide important data on the prognostic role of BRAF
mutation. Whether BRAF status has any predictive role for irinotecan-based
chemotherapy needs to be examined by additional studies.
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BRAF mutation and clinical outcome in colon cancer.
A-C. Kaplan-Meier curves according to BRAF mutation in 506 stage III colon cancers for
recurrence-free survival (RFS) (A), disease-free survival (DFS) (B), and overall survival
(OS) (C). The y axis indicates the survival probability. D-F. Kaplan-Meier curves for RFS
(D), DFS (E) and OS (F) according to treatment arm and BRAF mutation status. G. Proposed
strategy for prognostication of colon cancer by MSI and BRAF tests. DFS, disease-free
survival; FU/LV, 5-fluorouracil and leucovorin; IFL, irinotecan, 5-fluorouracil and
leucovorin; MSI, microsatellite instability; MSS, microsatellite stable; Mut, mutant; OS,
overall survival; RFS, recurrence-free survival; WT, wild-type.
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Table 1
Baseline characteristics according to BRAF mutational status in stage III colon cancer




Total N 506 431 75
Sex 0.0044
Male 274 (54%) 245 (57%) 29 (39%)
Female 232 (46%) 186 (43%) 46 (61%)
Age (years) <0.0001
<50 99 (20%) 97 (23%) 2 (2.7%)
50-59 131 (26%) 121 (28%) 10 (13%)
60-69 156 (31%) 125 (29%) 31 (41%)
≥70 120 (24%) 88 (20%) 32 (43%)
Mean age SD 59.7 11.5 58.6 11.7 66.5 8.0 <0.0001
Body mass index (BMI; kg/m2) 0.77
<25 164 (32%) 137 (32%) 27 (36%)
25-29 185 (37%) 159 (37%) 26 (35%)
≥30 157 (31%) 135 (31%) 22 (29%)
Family history of colorectal cancer in
any first-degree relative
0.11
(−) 419 (84%) 361 (85%) 58 (77%)
(+) 82 (16%) 65 (15%) 17 (23%)
Tumor location <0.0001
Proximal (cecum to transverse colon) 287 (57%) 219 (51%) 68 (92%)
Distal (splenic flexure to sigmoid) 214 (43%) 208 (49%) 6 (8.1%)
pT stage 0.29
pT1-pT2 58 (12%) 50 (12%) 8 (11%)
pT3 409 (82%) 351 (82%) 58 (78%)
pT4 33 (6.6%) 25 (5.9%) 8 (11%)
pN stage 0.13
pN1 318 (63%) 277 (65%) 41 (55%)
pN2 185 (37%) 152 (35%) 33 (45%)
AJCC tumor stage 0.51
IIIA 48 (9%) 42 (10%) 6 (8%)
IIIB 268 (53%) 233 (54%) 35 (47%)
IIIC 185 (36%) 152 (35%) 33 (44%)
III, unknown substage 5 (1%) 4 (1%) 1 (1%)
Performance status score 0.11
0 387 (76%) 335 (78%) 52 (69%)
1-2 119 (24%) 96 (22%) 23 (31%)
Clinical bowel perforation 0.10
(−) 475 (96%) 407 (96%) 68 (92%)
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(+) 22 (4%) 16 (4%) 6 (8%)
Clinical bowel obstruction 0.91
(−) 390 (78%) 333 (78%) 57 (77%)
(+) 113 (22%) 96 (22%) 17 (23%)
Microsatellite instability (MSI) status* <0.0001
Microsatellite stable (MSS) 428 (85%) 387 (90%) 41 (55%)
MSI-high 77 (15%) 43 (10%) 34 (45%)
KRAS mutation status <0.0001
Wild-type 330 (65%) 256 (59%) 74 (99%)
Mutant 176 (35%) 175 (41%) 1 (1.3%)
Treatment arm 0.10
FU/LV 267 (53%) 234 (54%) 33 (44%)
IFL 239 (47%) 197 (46%) 42 (56%)
(%) indicates the proportion of tumors with a specific clinical or molecular feature in BRAF-wild-type tumors (or BRAF-mutated tumors). There
were cases with missing value/status for some of the variables.
AJCC, American Joint Committee on Cancer; FU/LV, 5-fluorouracil and leucovorin; IFL, irinotecan, 5-fluorouracil and leucovorin; SD, standard
deviation.
*
For 28 cases without MSI results by PCR, those with loss of MLH1 or MSH2 were classified as MSI-high, and those with intact expression of
MLH1 and MSH2 as MSS, because concordance between MSI PCR and immunohistochemistry for MLH1 and MSH2 was very high (97%) among
cases with both results available (23).
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